Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Buy” from Analysts

Sanofi (NASDAQ:SNY) has been given an average recommendation of “Buy” by the four brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $60.00.

Several research firms recently commented on SNY. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday. They issued a “neutral” rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Institutional Investors Weigh In On Sanofi

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Charles Schwab Investment Management Inc. raised its stake in shares of Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after acquiring an additional 33,105 shares during the period. Arkadios Wealth Advisors increased its holdings in Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after purchasing an additional 751 shares during the last quarter. Geode Capital Management LLC raised its position in Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. lifted its stake in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, Kentucky Trust Co purchased a new position in shares of Sanofi during the fourth quarter worth $436,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Down 1.4 %

SNY stock opened at $57.79 on Friday. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a 50-day simple moving average of $54.39 and a 200-day simple moving average of $52.92. The stock has a market capitalization of $146.66 billion, a P/E ratio of 23.21, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.